Effect of PUFAs oral administration on the amount of Apoptotic Caspases Enzymes in gastric cancer patients undergoing chemotherapy

Background and Aim : Gastric cancer is the fourth most common cancer and the second case of death in the world. According to the studies, the gastric cancer is relatively sensitive to chemotherapy. The aim of this study was to investigate the association of oral administer PUFAs with Caspase enzymes in patients with gastric cancer under chemotherapy. Methods : This study is a Clinical Trial that target group is patients with gastric cancer recognized for the first time and cured under chemotherapy. Thirty-four patients were chosen in two groups. At control group, chemotherapy started with Cis-Platin and in case group, chemotherapy with CisPlatin plus PUFAs supplement in the scale of 3600 mg daily and in length of three courses. Biopsy samples from tumor were taken patients before and after chemotherapy. Levels of mRNA and protein expression of caspase3, 8, 9 samples were measured in biopsy samples by Real-Time PCR and Frozen Section methods. Results : In Case group, caspase-3 and 9 gene expression amount, before and after chemotherapy has been increased significantly in comparison with control group (Respectively p=0.006 and p<0.0001). But, caspase-8 gene expression showed no significant difference in both groups (p = 0.618). In Case group, caspase-3 and 9 proteins percent, before and after chemotherapy has been increased significantly in comparison with control group (Respectively p=0.001 and p<0.0001). But, percent of caspase-8 protein showed no significant difference in both groups (p = 0.349). Conclusion : According to the results of present study, it appears that oral administration of PUFAs can elevated the efficacy of chemotherapy agent. As it enhances caspase-3 and 9 gene expression, which is an important induce the apoptosis process.

Gastric Adenocarcinoma, Apoptosis, Omega Fatty Acids, Caspases Enzymes, Chemoresistance